Helixor®

Mistletoe therapy for tumor patients

Improvement in quality of life for breast cancer patients during chemo-therapy with Helixor® A adjuvant therapy

Tröger, W.: Helixor®-therapy during chemotherapy. Results of a randomized clinical trial. Onkologie 33(suppl 2), 34 (2010)

Deutscher Krebskongress 2010

Helixor

Bringing Life to Life.

Positive influence of Helixor® A adjuvant therapy on the quality of life of breast cancer patients, which is impaired by chemotherapy, and on the decrease in the number of neutrophilic granulocytes

Quality of life was ascertained using the EORTC QLQ-C30 questionnaire.

With 4 function and 6 symptom scales, there was a significant difference in the average score in favor of the patients also treated with Helixor® A.



In the functional scales, an *increase* in the score corresponds to "improvement", while a *decrease* in the score in the symptom scales represents "improvement". Group comparison of the mean values using Dunnett's test.



Neutropenia occurred less frequently in the Helixor® A group than in the control group:

occurrence in 15.4% vs. 25.0% of the patients (p = 0.505, Fisher's exact test).



Results

- Helixor® group better than control group in almost all EORTC dimensions
  - Significant in 10 of 15 dimensions ($p < 0.05$)
  - Differences clinically relevant (difference at least 5 score points)
- Neutropenia less frequent in Helixor® group than in control group

Good tolerance

- The only adverse effect observed for Helixor® A was 42 excessive, but spontaneously reversible, local reactions following a total of 1,527 injections (2.75%).
- Conclusion:
  high level of drug safety for Helixor® A during chemotherapy.

Conclusions

Adjuvant treatment with Helixor® A during chemotherapy

- improves the quality of life for breast cancer patients
- reduces the frequency of chemotherapy-induced neutropenia.

Patient population:	breast cancer patients following surgery ($T_{1-3}N_{0-2}M_0$) with planned chemotherapy (6 cycles CAF)
Aim of the study:	testing the influence of Helixor® A adjuvant treatment on quality of life and neutropenia
Study design:	prospective, randomized open pilot study (phase III)
Number of patients:	65 patients (34 Helixor®, 31 controls)
Comparison groups:	*Treatment group:* CAF + Helixor® A, 3x per week s.c., dose escalation from 1 mg → max. 200 mg *Control group:* CAF alone

Helixor®

Mistletoe therapy for tumor patients

Integrative oncology with Helixor®

Treating tumor patients integratively

In integrative oncology, the holistic mistletoe therapy from Helixor significantly improves the quality of life for patients at all stages of tumor treatment.

It stimulates self-healing and minimizes ailments, and its efficacy has been documented in numerous reviews and trials.

Helixor
Bringing Life to Life.

For questions on eligibility for reimbursement and for medical advice:

Telephone: 0049 (0)800 9353-440*
Fax: 0049 (0)800 9353-500*
E-mail: beratung@helixor.de

*free from German landlines

Helixor® A/-M/-P injection solution. Composition: Aqueous extract of fresh mistletoe leaves (1:20), special blend of winter and summer harvests in a standardized manufacturing process. Manufacturing of Helixor® A from fir mistletoe, Helixor® M from apple tree mistletoe, Helixor® P from pine tree mistletoe. The amount of fresh plant used to produce an ampoule is given in mg. **Therapeutic indications:** In accordance with the anthroposophic knowledge of man and nature. Malignant and benign tumorous diseases, stimulation of bone marrow activity, relapse prevention after tumor surgery, defined precancerous conditions. **Contraindications:** Acute inflammatory, feverish disorders, mistletoe allergy; pregnancy: if strictly indicated. **Adverse effects:** Local inflammatory reactions at the subcutaneous injection site, fever, flu-like symptoms, regional lymph node swelling, activation of inflammation, allergic reactions. **Note:** If there is a proneness to phlebitis, the injections are to be administered outside of the regions at risk of inflammation. In the event of pronounced hyperthyroidism, a delayed dosage increase is indicated. **Dosage:** s.c. according to the guidelines for treatment with Helixor®. In principle, begin with small doses. Increase dosage gradually while taking into account the patient's reaction. **Commercial forms:** Series packs (SE I - IV) with 7 ampoules; original packs (OP 0.01 - 100 mg) with 8 ampoules. Large packs and bundle packs (BP) with 4 x 7 amp. of SE II + SE IV also available.

Helixor Heilmittel GmbH & Co. KG • Fischermühle 1 • 72348 Rosenfeld • mail@helixor.de • www.helixor.de